ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare reimbursement policy for chronic wound healing products Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing product
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Health Issues HCR
Food and Drug Administration policy on chronic wound healing products H.R. 6000 (Cures 2.0 Act), Title III, regarding Food and Drug Administration policy on chronic wound healing products S. 4348 (FDASLA Act of 2022), regarding Food and Drug Administration policy on chronic wound healing products H.R. 7667 (Food and Drug Amendments of 2022), regarding Food and Drug Administration policy on chronic wound healing products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Defense DEF
Department of Defense research and development funding regarding regenerative medicine products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.